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Abstract
Several chimeric antigen receptor T-cell constructs (CAR-T cells) are currently approved for the treatment of B-cell
malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. Additionally, multiple other
products are being investigated and developed for other hematological malignancies and solid cancers. Patients
receiving CAR-T cells are at increased risk of infectious complications that lead to increased morbidity and inferior
mortality in these patients. In this review, we discuss the literature on the incidence and types of infection in patients in
the early and late-phase after CAR-T cells infusion. Additionally, we summarize the current literature on prophylaxis
against viral, bacterial, and fungal infections after CAR-T cells infusion and the utility of preventative and supportive
measures including intravenous immunoglobulins and myeloid growth factors.
Keywords: B-cell malignancies, CAR-T cells, Infections, Prevention

1. Introduction

S

ix chimeric antigen receptor T-cells (CAR-T
cells) products have been approved by the
United States Food and drug administration (USFDA) after demonstrating beneﬁcial outcomes in
trials [1e3]. Four of the approved products are CD19
targeting CAR T-cells used in B-cell malignancies
including acute lymphoblastic leukemia and nonHodgkin lymphoma [4]. Additionally, two BCMAdirected CAR-T products have been approved for
patients with multiple myeloma. CAR-T cell approvals are expected to increase in the upcoming
years given the current number of trials targeting
both hematologic malignancies and solid cancers [5].
With the increasing number of patients receiving
cellular therapies worldwide, identifying CAR-T
cells complications is crucial to mitigate these and

improve outcomes. Acute complications after CART cells including cytokine release syndrome (CRS)
and immune effector cell-associated neurotoxicity
syndrome (ICANS) are well deﬁned in literature [5].
However, other complications including cardiotoxicity, infectious complications, secondary malignancies and long-term effects are understudied
[6e8]. Some of the delayed toxicities such as prolonged cytopenia, B-cell aplasia, and hypogammaglobulinemia not just confer an increased infection
risk among CAR-T recipients but also diminish
vaccine responses resulting in a signiﬁcantly high
infection-related mortality. Hence, there is a critical
need to better understand these toxicities and
mitigate them to consolidate the remission success
conferred by CAR-T [9e11].
CAR-T cell therapy is expected to increase patients' susceptibility to infections due to several
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factors including lymphodepletion (LD) chemotherapy, underlying relapsed disease and immunosuppressive agents received after the infusion
[12,13]. Further, increasingly sophisticated and
multi-antigen targeting CARs and allowance for
prophylaxis usage of immunomodulators (such as in
cohort 6) will increase the cumulative dosage of
corticosteroids and interleukin blockers, further
compounding the infection risk [14]. Identiﬁcation
of patient- and treatment-related characteristics that
increase the risk of subsequent infections would
help risk stratify patients who may beneﬁt from
broader antimicrobial prophylaxis and timely diagnostic and therapeutic approaches.
In this review, we summarize major risk factors
and infections reported in patients receiving CAR-T
cells for the treatment of B-cell malignancies and the
available literature on infection prevention and
control.

2. Risk factors for CAR T cell associated
infections
Prior lines of therapy and CAR-T cells infusionrelated risk factors are thought to increase the
likelihood of infections in patients receiving CAR-T
cells infusion (See Table 1). Prior to receiving CAR-T
cell infusion, patients usually receive multiple lines
of therapy. For instance, in the ZUMA-1 trial around
70% of patients had three or more prior lines of
therapy [2]. This frequently includes cytotoxic
chemotherapy and hematopoietic cell transplantation which can have long-term effects on patients’ immune response due to an enhanced
cumulative net immunosuppression state. In one
analysis, around 40% of patients with infections
after CAR-T cell infusion had a prior autologous or
allogeneic transplant [13].

Table 1. Summary of the risk factors identiﬁed in literature.
Pre-CAR T cell infusion
1
2
3
4
5
6
7
8

Impaired baseline performance status
Number of prior lines of treatment
History of recent infections (within 100 days prior to infusion)
Adult patients
Pre-infusion hypogammaglobinemia
History of prior allogeneic transplant
ANC <500 cells per mm3.
Lymphodepleting chemotherapy

Post-CAR T cell infusion
1
2
3
4

Severe cytopenias (> Grade 3)
B cell aplasia
Hypogammaglobinemia
Cumulative immunomodulator exposure
(tocilizumab and corticosteroid) after CAR T cell infusion

The administration of CAR-T cells requires LD
chemotherapy necessitating the administration of
pre-infusion LD chemotherapy. The use of LD
chemotherapy can lead to immunosuppression
from cytopenia, hypogammaglobulinemia, and
impaired mucosal barriers. Severe cytopenias
(grade 3 and above) in the ﬁrst 4 weeks following the
administration of LD chemotherapy are common
and up to 17% of patients had persistent severe
cytopenia at 3 months post-infusion [15]. Of 83 reported patients with B-ALL who received CAR T
cell, pre-infusion hematopoietic cell transplant
(HCT) and LD chemotherapy with a regimen other
than cyclophosphamide plus ﬂudarabine, were
associated with increased infection [16].
B-cell directed CAR-T cells such as CD-19 CAR-T
cells can induce hypogammaglobulinemia and
long-term B-cell suppression [17]. IgG levels of
<400 mg/dL by 63 days post-CAR T-cells infusion,
was associated with increased infection risk [16].
Several studies have shown variable rates and
duration of hypogammaglobulinemia, and its
impact has been demonstrated consistently. For
instance, in an analysis of 71 CLL patients who
received CAR-T cell therapy, 44% of patients had
hypogammaglobulinemia prior to infusion, however, 81% of patients developed or continued to have
hypogammaglobulinemia post infusion [18]. The
levels of IgG can vary after infusion, for example, in
a review of 101 patients after receiving tisagenlecleucel or axicabtagene ciloleucel, 89% had hypogammaglobulinemia after infusion, with 57% and
13% being moderate and severe hypogammaglobulinemia, respectively [19]. Interestingly, only 23%
of patients had moderate to severe hypogammaglobulinemia prior to infusion. The onset of hypogammaglobulinemia can happen as early as 6 weeks
after infusion and can persist for years, indicating
the relationship between CAR-T cells persistence
and hypogammaglobulinemia [19].
Additionally, patients who developed post-infusion complications including CRS were reported to
be at a higher risk of infection [20]. For example,
Vora et al. [16] reviewed 83 patients who received
CD-19 CAR-T cells out of whom seven patients
developed grade 3 CRS from which 5 developed
infections. Patients with CRS frequently receive high
doses of corticosteroids and/or tocilizumab. Corticosteroids are known to predispose patients to infections, whereas tocilizumab carries a theoretical
risk for infection however, clinical data is conﬂicting.
Other reported risk factors included CAReT-cell
dose, recent infection within the past 100 days, age
>18, and infection 30 days before LD chemotherapy
[13,20].
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3. Incidence and types of infections
For the reasons listed above, higher incidence of
infections was reported in patients after CAR-T cells
for B-cell malignancies. It should be noted that the
majority of studies are for patients who received
CD-19 targeting CAR-T cells. The literature is heterogenic in regard to the other types of CAR-T cells
used for different primary diseases. Below, we will
discuss the infections according to time of onset
after CAR-T cells infusion.
3.1. Early infections (ﬁrst 30 days)
The incidence of infections in the early phase after
CAR-T cells was variable in different studies. . For
instance, Vora et al. [16] reported that 40% of the 83
ALL patients treated with CAR T-cells had an
infection during the ﬁrst 30 days after infusion,
including four patients who had two infections
during that period. Dayagi et al. [21] reported data
from 88 patients receiving CD28-based CD19 CART cells, 36 infections were reported in 24 patients in
the ﬁrst 30 days after infusion.
The type of infection varied between the studies;
however, bacteremia and localized bacterial infections followed by viral infections were the most
frequently reported infections during this early
phase post-infusion. The ratio of bacterial infections
ranged between 50 and 70% in studies [20,21]. Some
studies have shown higher cumulative incidence of
viral infections, for instance, Baird et al. [15] reported 19 patients (46.3%) who developed infections
after receiving axicabtagene ciloleucel therapy for
large B-cell lymphoma, out of which viral respiratory tract infections were the commonest. Fungal
infections were less common in the ﬁrst 30 days
across the studies, for instance, Vora et al. [16] reported only one case of fungal infection in 83 patients in the ﬁrst 4 weeks post infusion. In another
study examining 280 patients who received CD19+
CAR T-cells, only 5 developed invasive fungal
infection. This was despite signiﬁcant early and late
on-target off-tumor CAR-T toxicities and without
antifungal prophylaxis [22].
The microbiological identiﬁcation of organisms is
reportedly around 70% of cases (Stewart and Henden 2020). Common sites include bloodstream, lung,
genitourinary, soft tissues, however, bacteremia is
the most encountered infection. Both gram-negative
and gram-positive bacteremia were reported in patients after CAR-T cells with variable ratios. Clostridioides difﬁcile colitis was also frequently reported
in the literature [12]. On the other hand, most
common viral infections include respiratory viruses
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and HSV. Cytomegalovirus, EpsteineBarr virus,
and other herpesviruses are less commonly
encountered after CAR-T cells [23]. Fungal infections including candida and aspergillus were reported but less frequently.
3.2. Late infections (after 30 days)
Incidence of infections decreases after the ﬁrst 30
days post-infusion [16]. The majority of studies reported higher incidence of viral infections after the
ﬁrst 30 days. For instance, Logue et al. [24] reported
the data from 85 patients with relapsed/refractory Bcell lymphoma who received axicabtagene ciloleucel, 24 bacterial infections were reported in the
ﬁrst 30 days, in comparison to 13 infections beyond
d+30. On the other hand, 12 viral infections were
reported in the ﬁrst 30 days compared to 19 infections after 30 days, with the majority being upper
respiratory tract infections. Higher incidence of
fungal infections was reported in many studies after
day+30 [15,20], but this was not consistent in all
studies [23,24].
The majority of viral infections in this period are
respiratory tract infections [15,24], with rhinovirus
being the most common pathogen identiﬁed [12].
CMV reactivation and other herpesviruses remain
uncommon in this later period. Fungal infections are
the least common compared to viral and bacterial
infections. Invasive fungal infections after CAR-T
cells are usually reported in patients with risk factors including prolonged neutropenia and chronic
steroid therapy. Pneumocystis jirovecii infections have
rarely been reported in literature which is likely
explained by the use of prophylactic agents [13,25].
Few studies have provided long-term follow-up
data for infections one year after the infusion. Locke
et al. [26] reported follow-up data for patients 12
months post-infusion, only two patients out of 108
patients had grade >3 infections (one patient with
pulmonary infection and one patient with two episodes of bacteremia). Further studies are needed
examining longer term infectious complications and
their impact on remission and patients’ survival.

4. Infections prevention
Patients who are planned to receive CAR-T cells
should be screened for opportunistic and chronic
infections including human immunodeﬁciency virus
(HIV), hepatitis B virus (HBV), hepatitis C virus, etc.
Additionally, the risk of reactivation of diseases such
as mycobacterium tuberculosis and strongyloides
should be considered given the possibility of
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corticosteroids and tocilizumab use in case of cytokine release syndrome [23].
4.1. Antimicrobial prophylaxis
As discussed previously, CAR T-cells patients are
at higher risk of infectious complications and prophylaxis is recommended in this population however the guidelines are not uniform (See Table 2).
For instance, around 50% of patients received
antibacterial prophylaxis in a retrospective analysis
of 60 patients treated with CD-19 targeting CAR-T
[20]. Several centers limit prophylaxis to patients
with severe neutropenia (absolute neutrophilic
count <500), however, other centers start antibacterial prophylactically post-infusion [20,27,28]. Fluoroquinolones, such as levoﬂoxacin, are widely
used, however, other options include beta-lactams
[27,29].
The use of antivirals is more common compared
to antibacterial prophylaxis, particularly against
HSV. Wudhikarn et al. [20] reported that all patients
in their analysis were on antivirals against HSV.
Regimens including acyclovir or valacyclovir are
generally initiated along with the lymphodepletion
chemotherapy. Most guidelines recommend 3e6
months of therapy [20,27]. The use of other prophylactic antivirals against viruses such as cytomegalovirus (CMV) is not recommended for all
patients, as the incidence of such infections is low
after CAR-T cells infusion. Patients planned to
receive CAR-T cells should be screened for opportunistic and chronic viral infections particularly
Human immunodeﬁciency virus (HIV), hepatitis B
virus (HBV) and Hepatitis C virus [23]. In case of any
positive testing, initiation of treatment and referral
to specialists is needed to prevent reactivation and

progression of these infections. Patients with HBV
are recommended to receive entecavir prior to
infusion and up to 6e12 months after infusion to
prevent reactivation [23].
The use of anti-fungal medications against
candida is usually initiated at the onset of neutropenia and continued until ANC recovery [20,27].
The deﬁnition of neutrophilic recovery varies by
institution, examples of such deﬁnitions include
ANC >1000 or ANC >500 for three days [20,28]. The
suggested regimen is ﬂuconazole, with micafungin
being an alternative in case of any contraindications
[27]. Additionally, patients at risk of mold infections,
such as patients with prolonged neutropenia and
corticosteroid use, should receive antifungals with
anti-mold properties such as posaconazole or voriconazole [23]. However, several institutional studies
showed low rates of fungal infections which raises
the question on the necessity of anti-fungal prophylaxis [22].
Patients receiving CAR-T cells should receive
prophylaxis against pneumocystis jirovecii, preferably
with trimethoprim-sulfamethoxazole or pentamidine (in cytopenic patients), alternatively, dapsone
and atovaquone can be used [20,27]. The recommended duration varies in literature, but it is
generally recommended to initiate at d+30 and
continue prophylaxis for 3e6 months if CD4 count is
higher than 200.
4.2. Supportive care
Multiple interventions have been investigated to
prevent infections by addressing common infectioncontributors after CAR-T cells infusion. For
instance, hypogammaglobulinemia and B-cell
aplasia are almost universal after receiving B-cell

Table 2. Antimicrobials used in infectious prophylaxis after CAR-T cells infusion.
Prophylaxis

First Choicea

Alternativesa

Suggested approaches

Antibacterial

Fluoroquinolones (Such as
levoﬂoxacin 500 mg PO daily).
Acyclovir 800 mg PO BID

Beta-lactams such as:
Cefpodoxime 200 mg PO BID
Valacyclovir 500 mg PO daily
Famciclovir 250 mg PO BID
Micafungin 50 mg IV q24h
(if signiﬁcant LFT or T-bili increase)

Starts with neutropenia and
until neutrophil recovery.
Starts with LD chemotherapy
and continue for at least 6 months.
Starts with onset of neutropenia
and continue until neutrophil
recovery.

Inhaled Pentamidine 300 mg monthly
Pentamidine 4 mg/kg IV monthly
Dapsone 100 mg PO daily
Atovaquone 1500 mg PO daily

Starts day +30 and continue
for 3 months or more if
CD4<200 cell/mL.

Antiviral (against
HSV/VZV)
Antifungals

Anti-PJP
pneumonia

Fluconazole 200 mg PO daily
If high risk of mold infectionb:
Posaconazole 300 mg PO daily
or voriconazole 200 mg PO BID
Trimethoprim/Sulfamethoxazole
1 double-strength PO three times
a week.

Abbreviations: PO: by mouth; BID: twice daily; HSV: Herpes Simplex Virus; VZV: Varicella Zoster Virus; LD: lymphodepleting
chemotherapy; LFTs: Liver function tests, PJP: Pneumocystis jiroveci pneumonia.
a
Some doses require adjustments according to renal or liver function.
b
Patients on high dose of corticosteroids or prolonged neutropenia.
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targeting CAR-T cells [17]. The data on the utility of
intravenous immune globulin (IVIG) to prevent infections is inconsistent [18,20]. However, it should
be noted that high-quality evidence is lacking. Thus,
considering prophylactic IVIG in patients with severe hypogammaglobulinemia (IgG 400 mg/dl) or
moderate hypogammaglobulinemia with recurrent
infections has been suggested [30].
The use of Granulocyte Colony-Stimulating Factor (G-CSF) to shorten the duration of neutropenia,
and as such decrease the risk of infections, is a
widely accepted intervention in hematology. However, published data addressing the use of G-CSF
for neutropenic patients post-CAR T-cells is
controversial [13,31,32]. Although studies have
shown that the use of G-CSF decreases the duration
of neutropenia, the role of G-CSF in decreasing infections is less consistent throughout the studies
[33,34]. Additionally, administering G-CSF may increase the risk and/or severity of CRS and ICANS
given the increased proliferation of macrophages
and monocytes that might lead to increased cytokine release [11,34,35]. A recent retrospective study
including 70 patients out of which around half
received G-CSF showed that patients receiving GCSF had shorter duration of neutropenia, similar
incidence in infection and CRS, however, longer
CRS duration [35].
Guidance on vaccination after CAR-T cells is still
generally lacking and variable depending on patients’ prior and future therapies. Suggested recommendation includes receiving inactivated vaccines
and live attenuated vaccines, 6 months and 1 year
after infusion, respectively [23]. Vaccines should be
avoided for two months after receiving IVIG.

5. Conclusion
The topic of infectious complications post CAR
T-cell will become increasingly important with the
increasing number of patients treated with this
modality and the expected increase in the approved
products and indications. The literature currently
available is scarce and insufﬁcient to appropriately
inform practitioners and unify guidelines. However,
we can capitalize on the currently available literature and try to treat CAR T-cell patients accordingly.
High quality research should be promoted to look
into this issue, ideally in a prospective setting but
if logistically difﬁcult, registry level studies using
large datasets from collaborative groups can answer
many questions. Ideally, we should unify efforts
to adopt a stratiﬁcation strategy and implement
measures to mitigate the infection risk according to
the strata.
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